Lastly, in a multi-targeting approach, the inhibition of NF-κB by activators of the lysosomal degradation pathways could act not only on the tumor component itself, but indirectly on the role of NF-κB in the regulation of the tumor microenvironment (Chang et al., 2013). The gene discussed is NFKB1; the disease is neoplasm.